This article is more than 5 years old. Information may no longer be current.
Conventus receives FDA 510(k) clearance for distal, proximal ulna fracture repair systems
Click Here to Manage Email Alerts
Conventus Orthopaedics Inc. announced it has received FDA 510(k) clearance to market its Conventus Cage distal ulna and proximal ulna systems for fracture repair.
According to a company press release, the Conventus Cage uses nitinol which allows the cage to expand within the bone to create stable fixation and prevent collapse of the fracture repair. The self-expanding scaffolds reportedly allow for reliable and less invasive repair and may also decrease the chance of a secondary procedure compared with the use of alternative methods.
“The approval of this additional indication reflects our commitment to provide more innovative solutions and options for surgeons working to repair orthopedic fractures throughout the body,” Paul Buckman, Conventus president and chief executive officer, said in the release. “Our overall goal is to provide a complete platform technology enabling surgeons to treat all trauma and fracture repairs from a 3-dimensional approach.”
Reference: